Key statistics
On Friday, Perspective Therapeutics Inc (CATX:ASQ) closed at 4.71, -23.54% below its 52-week high of 6.16, set on Jan 29, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 4.72 |
|---|---|
| High | 4.78 |
| Low | 4.45 |
| Bid | 4.65 |
| Offer | 4.72 |
| Previous close | 4.63 |
| Average volume | 12.97m |
|---|---|
| Shares outstanding | 113.91m |
| Free float | 101.62m |
| P/E (TTM) | -- |
| Market cap | 527.42m USD |
| EPS (TTM) | -1.46 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
- Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
- Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
- Perspective Therapeutics to Participate in Upcoming December Conferences
- Perspective Therapeutics to Participate in Upcoming November Conferences
- Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
- Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025
- Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
More ▼
